-
2
-
-
0028955323
-
Incidence of myelodysplastic syndromes in a Swedish population
-
Rådlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995;54(3):153-156.
-
(1995)
Eur J Haematol
, vol.54
, Issue.3
, pp. 153-156
-
-
Rådlund, A.1
Thiede, T.2
Hansen, S.3
Carlsson, M.4
Engquist, L.5
-
3
-
-
0030016365
-
Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population
-
Maynadié M, Verret C, Moskovtchenko P, Mugneret F, Petrella T, Caillot D, Carli PM. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74(2):288-290.
-
(1996)
Br J Cancer
, vol.74
, Issue.2
, pp. 288-290
-
-
Maynadié, M.1
Verret, C.2
Moskovtchenko, P.3
Mugneret, F.4
Petrella, T.5
Caillot, D.6
Carli, P.M.7
-
4
-
-
0035375406
-
Epidemiological features of myelodysplastic syndromes: Results from regional cancer surveys and hospital-based statistics
-
Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73(4):405-410.
-
(2001)
Int J Hematol
, vol.73
, Issue.4
, pp. 405-410
-
-
Aul, C.1
Giagounidis, A.2
Germing, U.3
-
5
-
-
3943093187
-
No increase in age-specific incidence of myelodysplastic syndromes
-
Germing U, Strupp C, Kü ndgen A, Bowen D, Aul C, Haas R, Gattermann N. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89(8):905-910.
-
(2004)
Haematologica
, vol.89
, Issue.8
, pp. 905-910
-
-
Germing, U.1
Strupp, C.2
Ndgen, A.K.3
Bowen, D.4
Aul, C.5
Haas, R.6
Gattermann, N.7
-
6
-
-
47249150213
-
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
-
Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52.
-
(2008)
Blood
, vol.112
, Issue.1
, pp. 45-52
-
-
Rollison, D.E.1
Howlader, N.2
Smith, M.T.3
-
7
-
-
80055110031
-
Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry
-
Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011;35(12):1591-1596.
-
(2011)
Leuk Res.
, vol.35
, Issue.12
, pp. 1591-1596
-
-
Neukirchen, J.1
Schoonen, W.M.2
Strupp, C.3
Gattermann, N.4
Aul, C.5
Haas, R.6
Germing, U.7
-
8
-
-
0031762071
-
A patient-oriented approach to treatment of myelodysplastic syndromes
-
Cazzola M, Anderson JE, Ganser A, Hellström-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 1998;83(10):910-935.
-
(1998)
Haematologica
, vol.83
, Issue.10
, pp. 910-935
-
-
Cazzola, M.1
Anderson, J.E.2
Ganser, A.3
Hellström-Lindberg, E.4
-
9
-
-
12244277678
-
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology
-
Italian Society of Hematology
-
Alessandrino EP, Amadori S, Barosi G, et al; Italian Society of Hematology. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002;87(12):1286-1306.
-
(2002)
Haematologica
, vol.87
, Issue.12
, pp. 1286-1306
-
-
Alessandrino, E.P.1
Amadori, S.2
Barosi, G.3
-
10
-
-
0037272767
-
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes
-
UK MDS Guidelines Group
-
Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J; UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120(2):187-200.
-
(2003)
Br J Haematol
, vol.120
, Issue.2
, pp. 187-200
-
-
Bowen, D.1
Culligan, D.2
Jowitt, S.3
Kelsey, S.4
Mufti, G.5
Oscier, D.6
Parker, J.7
-
11
-
-
0037707487
-
Strategy for randomised clinical trials in rare cancers
-
Tan SB, Dear KB, Bruzzi P, Machin D. Strategy for randomised clinical trials in rare cancers. BMJ. 2003;327(7405):47-49.
-
(2003)
BMJ
, vol.327
, Issue.7405
, pp. 47-49
-
-
Tan, S.B.1
Dear, K.B.2
Bruzzi, P.3
Machin, D.4
-
13
-
-
0035845305
-
A new system for grading recommendations in evidence based guidelines
-
Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334-336.
-
(2001)
BMJ
, vol.323
, Issue.7308
, pp. 334-336
-
-
Harbour, R.1
Miller, J.2
-
15
-
-
0022600206
-
A method for the detailed assessment of the appropriateness of medical technologies
-
Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986;2(1):53-63.
-
(1986)
Int J Technol Assess Health Care
, vol.2
, Issue.1
, pp. 53-63
-
-
Brook, R.H.1
Chassin, M.R.2
Fink, A.3
Solomon, D.H.4
Kosecoff, J.5
Park, R.E.6
-
16
-
-
33846912251
-
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer
-
Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25(3):292-300.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.3
, pp. 292-300
-
-
Le Deley, M.C.1
Suzan, F.2
Cutuli, B.3
-
17
-
-
34948845600
-
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
-
Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25(27):4285-4292.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.27
, pp. 4285-4292
-
-
Czuczman, M.S.1
Emmanouilides, C.2
Darif, M.3
-
18
-
-
79952330285
-
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: A 20-year retrospective follow-up study in patients with lymphoma
-
Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814-824.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.7
, pp. 814-824
-
-
Tarella, C.1
Passera, R.2
Magni, M.3
-
19
-
-
84870158821
-
Myelodysplastic syndrome and benzene exposure among petroleum workers: An international pooled analysis
-
Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst. 2012;104(22):1724-1737.
-
(2012)
J Natl Cancer Inst
, vol.104
, Issue.22
, pp. 1724-1737
-
-
Schnatter, A.R.1
Glass, D.C.2
Tang, G.3
Irons, R.D.4
Rushton, L.5
-
20
-
-
16544391755
-
Mutation of CEBPA in familial acute myeloid leukemia
-
Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351(23):2403-2407.
-
(2004)
N Engl J Med.
, vol.351
, Issue.23
, pp. 2403-2407
-
-
Smith, M.L.1
Cavenagh, J.D.2
Lister, T.A.3
Fitzgibbon, J.4
-
21
-
-
71849087592
-
Telomere diseases
-
Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-2365.
-
(2009)
N Engl J Med.
, vol.361
, Issue.24
, pp. 2353-2365
-
-
Calado, R.T.1
Young, N.S.2
-
22
-
-
80053383273
-
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia
-
Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10):1012-1017.
-
(2011)
Nat Genet
, vol.43
, Issue.10
, pp. 1012-1017
-
-
Hahn, C.N.1
Chong, C.E.2
Carmichael, C.L.3
-
23
-
-
84868613789
-
Molecular pathogenesis and clinical management of Fanconi anemia
-
Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012;122(11):3799-3806.
-
(2012)
J Clin Invest.
, vol.122
, Issue.11
, pp. 3799-3806
-
-
Kee, Y.1
D'Andrea, A.D.2
-
24
-
-
84863449106
-
Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia
-
Holme H, Hossain U, Kirwan M, Walne A, Vulliamy T, Dokal I. Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J Haematol. 2012;158(2):242-248.
-
(2012)
Br J Haematol
, vol.158
, Issue.2
, pp. 242-248
-
-
Holme, H.1
Hossain, U.2
Kirwan, M.3
Walne, A.4
Vulliamy, T.5
Dokal, I.6
-
25
-
-
0035883086
-
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome
-
Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98(4):979-987.
-
(2001)
Blood
, vol.98
, Issue.4
, pp. 979-987
-
-
Stetler-Stevenson, M.1
Arthur, D.C.2
Jabbour, N.3
-
26
-
-
0038578247
-
Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation
-
Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394-403.
-
(2003)
Blood
, vol.102
, Issue.1
, pp. 394-403
-
-
Wells, D.A.1
Benesch, M.2
Loken, M.R.3
Vallejo, C.4
Myerson, D.5
Leisenring, W.M.6
Deeg, H.J.7
-
27
-
-
20844445116
-
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome
-
Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005;19(5):776-783.
-
(2005)
Leukemia
, vol.19
, Issue.5
, pp. 776-783
-
-
Malcovati, L.1
Della Porta, M.G.2
Lunghi, M.3
-
28
-
-
33746583139
-
Diagnostic application of flow cytometric characteristics of CD341 cells in lowgrade myelodysplastic syndromes
-
Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD341 cells in lowgrade myelodysplastic syndromes. Blood. 2006;108(3):1037-1044.
-
(2006)
Blood
, vol.108
, Issue.3
, pp. 1037-1044
-
-
Ogata, K.1
Kishikawa, Y.2
Satoh, C.3
Tamura, H.4
Dan, K.5
Hayashi, A.6
-
29
-
-
38949196414
-
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
-
van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111(3):1067-1077.
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1067-1077
-
-
Van De Loosdrecht, A.A.1
Westers, T.M.2
Westra, A.H.3
Dräger, A.M.4
Van Der Velden, V.H.5
Ossenkoppele, G.J.6
-
30
-
-
36148993604
-
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
-
Mohamedali A, Gäken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110(9):3365-3373.
-
(2007)
Blood
, vol.110
, Issue.9
, pp. 3365-3373
-
-
Mohamedali, A.1
Gäken, J.2
Twine, N.A.3
-
31
-
-
51649103380
-
Whole genome scanning as a cytogenetic tool in hematologic malignancies
-
Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008;112(4):965-974.
-
(2008)
Blood
, vol.112
, Issue.4
, pp. 965-974
-
-
Maciejewski, J.P.1
Mufti, G.J.2
-
33
-
-
67649876132
-
Acquired mutations in TET2 are common in myelodysplastic syndromes
-
Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842.
-
(2009)
Nat Genet
, vol.41
, Issue.7
, pp. 838-842
-
-
Langemeijer, S.M.1
Kuiper, R.P.2
Berends, M.3
-
34
-
-
79959794787
-
Clinical effect of point mutations in myelodysplastic syndromes
-
Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
-
(2011)
N Engl J Med.
, vol.364
, Issue.26
, pp. 2496-2506
-
-
Bejar, R.1
Stevenson, K.2
Abdel-Wahab, O.3
-
35
-
-
79955945973
-
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
-
Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117(17):4552-4560.
-
(2011)
Blood
, vol.117
, Issue.17
, pp. 4552-4560
-
-
Tiu, R.V.1
Gondek, L.P.2
O'Keefe, C.L.3
-
36
-
-
80053900941
-
Frequent pathway mutations of splicing machinery in myelodysplasia
-
Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
-
(2011)
Nature
, vol.478
, Issue.7367
, pp. 64-69
-
-
Yoshida, K.1
Sanada, M.2
Shiraishi, Y.3
-
37
-
-
80054010617
-
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
-
Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
-
Papaemmanuil E, Cazzola M, Boultwood J, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384-1395.
-
(2011)
N Engl J Med.
, vol.365
, Issue.15
, pp. 1384-1395
-
-
Papaemmanuil, E.1
Cazzola, M.2
Boultwood, J.3
-
38
-
-
83455234787
-
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
-
Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative
-
Malcovati L, Papaemmanuil E, Bowen DT, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-6246.
-
(2011)
Blood
, vol.118
, Issue.24
, pp. 6239-6246
-
-
Malcovati, L.1
Papaemmanuil, E.2
Bowen, D.T.3
-
39
-
-
0019952276
-
Proposals for the classification of the myelodysplastic syndromes
-
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
-
(1982)
Br J Haematol
, vol.51
, Issue.2
, pp. 189-199
-
-
Bennett, J.M.1
Catovsky, D.2
Daniel, M.T.3
Flandrin, G.4
Galton, D.A.5
Gralnick, H.R.6
Sultan, C.7
-
40
-
-
55549136382
-
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
-
International Working Group on Morphology of Myelodysplastic Syndrome
-
Mufti GJ, Bennett JM, Goasguen J, et al; International Working Group on Morphology of Myelodysplastic Syndrome. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712-1717.
-
(2008)
Haematologica
, vol.93
, Issue.11
, pp. 1712-1717
-
-
Mufti, G.J.1
Bennett, J.M.2
Goasguen, J.3
-
41
-
-
67650758078
-
Morphological evaluation of monocytes and their precursors
-
International Working Group on Morphology of Myelodysplastic Syndrome
-
Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R, Mufti GJ; International Working Group on Morphology of Myelodysplastic Syndrome. Morphological evaluation of monocytes and their precursors. Haematologica. 2009;94(7):994-997.
-
(2009)
Haematologica
, vol.94
, Issue.7
, pp. 994-997
-
-
Goasguen, J.E.1
Bennett, J.M.2
Bain, B.J.3
Vallespi, T.4
Brunning, R.5
Mufti, G.J.6
-
42
-
-
0027464926
-
Hypoplastic myelodysplastic syndrome: Incidence, morphology, cytogenetics, and prognosis
-
Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol. 1993;66(3):117-122.
-
(1993)
Ann Hematol
, vol.66
, Issue.3
, pp. 117-122
-
-
Maschek, H.1
Kaloutsi, V.2
Rodriguez-Kaiser, M.3
-
43
-
-
40749160472
-
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
-
Huang TC, Ko BS, Tang JL, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia. 2008;22(3):544-550.
-
(2008)
Leukemia
, vol.22
, Issue.3
, pp. 544-550
-
-
Huang, T.C.1
Ko, B.S.2
Tang, J.L.3
-
44
-
-
62649115028
-
Hypocellular myelodysplasia
-
Sloand EM. Hypocellular myelodysplasia. Hematol Oncol Clin North Am. 2009;23(2):347-360.
-
(2009)
Hematol Oncol Clin North Am
, vol.23
, Issue.2
, pp. 347-360
-
-
Sloand, E.M.1
-
45
-
-
59449096048
-
Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: Recommendations for a standardized approach
-
Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94(2):264-268.
-
(2009)
Haematologica
, vol.94
, Issue.2
, pp. 264-268
-
-
Bennett, J.M.1
Orazi, A.2
-
46
-
-
39449085348
-
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes
-
Buesche G, Teoman H, Wilczak W, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2008;22(2):313-322.
-
(2008)
Leukemia
, vol.22
, Issue.2
, pp. 313-322
-
-
Buesche, G.1
Teoman, H.2
Wilczak, W.3
-
47
-
-
59949102794
-
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes
-
Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754-762.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.5
, pp. 754-762
-
-
Della Porta, M.G.1
Malcovati, L.2
Boveri, E.3
-
48
-
-
24944524079
-
European consensus on grading bone marrow fibrosis and assessment of cellularity
-
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.
-
(2005)
Haematologica
, vol.90
, Issue.8
, pp. 1128-1132
-
-
Thiele, J.1
Kvasnicka, H.M.2
Facchetti, F.3
Franco, V.4
Van Der Walt, J.5
Orazi, A.6
-
49
-
-
84860545770
-
Assessment of dysplastic hematopoiesis: Lessons from healthy bone marrow donors
-
Parmentier S, Schetelig J, Lorenz K, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica. 2012;97(5):723-730.
-
(2012)
Haematologica
, vol.97
, Issue.5
, pp. 723-730
-
-
Parmentier, S.1
Schetelig, J.2
Lorenz, K.3
-
50
-
-
84875667215
-
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes
-
Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica. 2013;98(4):568-575.
-
(2013)
Haematologica
, vol.98
, Issue.4
, pp. 568-575
-
-
Senent, L.1
Arenillas, L.2
Luño, E.3
Ruiz, J.C.4
Sanz, G.5
Florensa, L.6
-
51
-
-
0036785306
-
Immunophenotypic clustering of myelodysplastic syndromes
-
Groupe d'Etude Immunologique des Leucémies GEIL
-
Maynadié M, Picard F, Husson B, et al; Groupe d'Etude Immunologique des Leucémies (GEIL). Immunophenotypic clustering of myelodysplastic syndromes. Blood. 2002;100(7):2349-2356.
-
(2002)
Blood
, vol.100
, Issue.7
, pp. 2349-2356
-
-
Maynadié, M.1
Picard, F.2
Husson, B.3
-
52
-
-
68049127978
-
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: A prospective validation study
-
Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94(8):1066-1074.
-
(2009)
Haematologica
, vol.94
, Issue.8
, pp. 1066-1074
-
-
Ogata, K.1
Della Porta, M.G.2
Malcovati, L.3
-
53
-
-
68049135888
-
Standardization of flow cytometry in myelodysplastic syndromes: Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
-
van de Loosdrecht AA, Alhan C, Béné MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94(8):1124-1134.
-
(2009)
Haematologica
, vol.94
, Issue.8
, pp. 1124-1134
-
-
Van De Loosdrecht, A.A.1
Alhan, C.2
Béné, M.C.3
-
54
-
-
84863785114
-
Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group
-
Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730-1741.
-
(2012)
Leukemia
, vol.26
, Issue.7
, pp. 1730-1741
-
-
Westers, T.M.1
Ireland, R.2
Kern, W.3
-
55
-
-
25444484409
-
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes
-
Solé F, Luño E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168-1178.
-
(2005)
Haematologica
, vol.90
, Issue.9
, pp. 1168-1178
-
-
Solé, F.1
Luño, E.2
Sanzo, C.3
-
56
-
-
39649094569
-
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients
-
Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395.
-
(2007)
Blood
, vol.110
, Issue.13
, pp. 4385-4395
-
-
Haase, D.1
Germing, U.2
Schanz, J.3
-
57
-
-
79956318358
-
Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system
-
Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;29(15):1963-1970.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.15
, pp. 1963-1970
-
-
Schanz, J.1
Steidl, C.2
Fonatsch, C.3
-
58
-
-
84858830672
-
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
-
Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-829.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.8
, pp. 820-829
-
-
Schanz, J.1
Tüchler, H.2
Solé, F.3
-
60
-
-
0035202361
-
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype
-
Rigolin GM, Bigoni R, Milani R, et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia. 2001;15(12):1841-1847.
-
(2001)
Leukemia
, vol.15
, Issue.12
, pp. 1841-1847
-
-
Rigolin, G.M.1
Bigoni, R.2
Milani, R.3
-
61
-
-
10744227653
-
Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients
-
Bernasconi P, Cavigliano PM, Boni M, et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia. 2003;17(11):2107-2112.
-
(2003)
Leukemia
, vol.17
, Issue.11
, pp. 2107-2112
-
-
Bernasconi, P.1
Cavigliano, P.M.2
Boni, M.3
-
62
-
-
0042563155
-
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: An Eastern Cooperative Oncology Group (ECOG) study
-
Cherry AM, Brockman SR, Paternoster SF, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res. 2003;27(12):1085-1090.
-
(2003)
Leuk Res.
, vol.27
, Issue.12
, pp. 1085-1090
-
-
Cherry, A.M.1
Brockman, S.R.2
Paternoster, S.F.3
-
63
-
-
74949108515
-
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies
-
Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27(36):6109-6116.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.36
, pp. 6109-6116
-
-
Makishima, H.1
Cazzolli, H.2
Szpurka, H.3
-
64
-
-
77955087290
-
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
-
Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
-
(2010)
Nat Genet
, vol.42
, Issue.8
, pp. 665-667
-
-
Nikoloski, G.1
Langemeijer, S.M.2
Kuiper, R.P.3
-
65
-
-
77952421834
-
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia
-
Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24(5):1062-1065.
-
(2010)
Leukemia
, vol.24
, Issue.5
, pp. 1062-1065
-
-
Boultwood, J.1
Perry, J.2
Pellagatti, A.3
-
66
-
-
79959317767
-
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes
-
Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29(18):2499-2506.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.18
, pp. 2499-2506
-
-
Thol, F.1
Friesen, I.2
Damm, F.3
-
67
-
-
79956291339
-
TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression
-
Jädersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. J Clin Oncol. 2011;29(15):1971-1979.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.15
, pp. 1971-1979
-
-
Jädersten, M.1
Saft, L.2
Smith, A.3
-
68
-
-
84888213154
-
Clinical and biological implications of gene mutations in MDS [abstract]
-
Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of gene mutations in MDS [abstract]. Leuk Res. 2013;37(Suppl 1):S9.
-
(2013)
Leuk Res.
, vol.37
, Issue.SUPPL. 1
-
-
Papaemmanuil, E.1
Gerstung, M.2
Malcovati, L.3
-
69
-
-
84555192302
-
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
-
Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44(1):53-57.
-
(2011)
Nat Genet
, vol.44
, Issue.1
, pp. 53-57
-
-
Graubert, T.A.1
Shen, D.2
Ding, L.3
-
70
-
-
34848824979
-
RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome
-
Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007;139(3):405-414.
-
(2007)
Br J Haematol
, vol.139
, Issue.3
, pp. 405-414
-
-
Chen, C.Y.1
Lin, L.I.2
Tang, J.L.3
-
71
-
-
77955715121
-
Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML
-
Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia. 2010;24(8):1528-1532.
-
(2010)
Leukemia
, vol.24
, Issue.8
, pp. 1528-1532
-
-
Dicker, F.1
Haferlach, C.2
Sundermann, J.3
-
72
-
-
84859856420
-
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
-
Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578-3584.
-
(2012)
Blood
, vol.119
, Issue.15
, pp. 3578-3584
-
-
Thol, F.1
Kade, S.2
Schlarmann, C.3
-
73
-
-
17344371122
-
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year followup
-
Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year followup. Leukemia. 1998;12(6):887-892.
-
(1998)
Leukemia
, vol.12
, Issue.6
, pp. 887-892
-
-
Padua, R.A.1
Guinn, B.A.2
Al-Sabah, A.I.3
-
74
-
-
0027181645
-
N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome
-
Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 1993;82(2):590-599.
-
(1993)
Blood
, vol.82
, Issue.2
, pp. 590-599
-
-
Paquette, R.L.1
Landaw, E.M.2
Pierre, R.V.3
-
75
-
-
79960255863
-
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
-
Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-1158.
-
(2011)
Leukemia
, vol.25
, Issue.7
, pp. 1153-1158
-
-
Walter, M.J.1
Ding, L.2
Shen, D.3
-
76
-
-
82855177869
-
Rare occurrence of DNMT3A mutations in myelodysplastic syndromes
-
Thol F, Winschel C, Lüdeking A, et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica. 2011;96(12):1870-1873.
-
(2011)
Haematologica
, vol.96
, Issue.12
, pp. 1870-1873
-
-
Thol, F.1
Winschel, C.2
Lüdeking, A.3
-
77
-
-
77955085750
-
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
-
Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
-
(2010)
Nat Genet
, vol.42
, Issue.8
, pp. 722-726
-
-
Ernst, T.1
Chase, A.J.2
Score, J.3
-
78
-
-
77952426827
-
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
-
Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094-1096.
-
(2010)
Leukemia
, vol.24
, Issue.5
, pp. 1094-1096
-
-
Kosmider, O.1
Gelsi-Boyer, V.2
Slama, L.3
-
79
-
-
21344440357
-
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes
-
Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207-1209.
-
(2005)
Blood
, vol.106
, Issue.4
, pp. 1207-1209
-
-
Steensma, D.P.1
Dewald, G.W.2
Lasho, T.L.3
-
80
-
-
84871988651
-
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
-
Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18-24.
-
(2013)
Nat Genet
, vol.45
, Issue.1
, pp. 18-24
-
-
Piazza, R.1
Valletta, S.2
Winkelmann, N.3
-
81
-
-
84880976662
-
Somatic SETBP1 mutations in myeloid malignancies
-
Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45(8):942-946.
-
(2013)
Nat Genet
, vol.45
, Issue.8
, pp. 942-946
-
-
Makishima, H.1
Yoshida, K.2
Nguyen, N.3
-
82
-
-
79955810336
-
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in. 80% of patients with TET2 and EZH2 being of high prognostic relevance
-
Grossmann V, Kohlmann A, Eder C, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in. 80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011;25(5):877-879.
-
(2011)
Leukemia
, vol.25
, Issue.5
, pp. 877-879
-
-
Grossmann, V.1
Kohlmann, A.2
Eder, C.3
-
84
-
-
0030019452
-
Refractory cytopenia with multilineage dysplasia: Further characterization of an 'unclassifiable' myelodysplastic syndrome
-
Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia. 1996;10(1):20-26.
-
(1996)
Leukemia
, vol.10
, Issue.1
, pp. 20-26
-
-
Rosati, S.1
Mick, R.2
Xu, F.3
Stonys, E.4
Le Beau, M.M.5
Larson, R.6
Vardiman, J.W.7
-
85
-
-
0030897009
-
International scoring system for evaluating prognosis in myelodysplastic syndromes
-
Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
-
(1997)
Blood
, vol.89
, Issue.6
, pp. 2079-2088
-
-
Greenberg, P.1
Cox, C.2
Le Beau, M.M.3
-
86
-
-
0036786901
-
The World Health Organization (WHO) classification of the myeloid neoplasms
-
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
-
(2002)
Blood
, vol.100
, Issue.7
, pp. 2292-2302
-
-
Vardiman, J.W.1
Harris, N.L.2
Brunning, R.D.3
-
87
-
-
67649431530
-
Acute myeloid leukaemia with myelodysplasia-related changes
-
Swerdlow SH, Campo E, Harris NL, et al, eds, Lyon, France: IARC
-
Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:124-126.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 124-126
-
-
Arber, D.A.1
Brunning, R.D.2
Orazi, A.3
-
88
-
-
70349256226
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
-
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
-
(2009)
Blood
, vol.114
, Issue.5
, pp. 937-951
-
-
Vardiman, J.W.1
Thiele, J.2
Arber, D.A.3
-
89
-
-
0021988836
-
Myelodysplastic syndromes: A scoring system with prognostic significance
-
Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol. 1985;59(3):425-433.
-
(1985)
Br J Haematol
, vol.59
, Issue.3
, pp. 425-433
-
-
Mufti, G.J.1
Stevens, J.R.2
Oscier, D.G.3
Hamblin, T.J.4
Machin, D.5
-
90
-
-
0024402407
-
Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients
-
Sanz GF, Sanz MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74(1):395-408.
-
(1989)
Blood
, vol.74
, Issue.1
, pp. 395-408
-
-
Sanz, G.F.1
Sanz, M.A.2
Vallespí, T.3
-
91
-
-
0027372507
-
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases
-
Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7(9):1315-1323.
-
(1993)
Leukemia
, vol.7
, Issue.9
, pp. 1315-1323
-
-
Morel, P.1
Hebbar, M.2
Lai, J.L.3
-
92
-
-
13444269356
-
Myelodysplastic syndromes-coping with ineffective hematopoiesis
-
Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536-538.
-
(2005)
N Engl J Med.
, vol.352
, Issue.6
, pp. 536-538
-
-
Cazzola, M.1
Malcovati, L.2
-
93
-
-
32144431895
-
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
-
Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.30
, pp. 7594-7603
-
-
Malcovati, L.1
Porta, M.G.2
Pascutto, C.3
-
94
-
-
28544433130
-
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
-
Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19(12):2223-2231.
-
(2005)
Leukemia
, vol.19
, Issue.12
, pp. 2223-2231
-
-
Germing, U.1
Hildebrandt, B.2
Pfeilstöcker, M.3
-
95
-
-
33845935489
-
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes
-
Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica. 2006;91(12):1596-1604.
-
(2006)
Haematologica
, vol.91
, Issue.12
, pp. 1596-1604
-
-
Germing, U.1
Strupp, C.2
Kuendgen, A.3
-
96
-
-
53549108334
-
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes
-
Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83(10):765-770.
-
(2008)
Am J Hematol
, vol.83
, Issue.10
, pp. 765-770
-
-
Kao, J.M.1
McMillan, A.2
Greenberg, P.L.3
-
97
-
-
53149113768
-
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
-
Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351-1361.
-
(2008)
Cancer
, vol.113
, Issue.6
, pp. 1351-1361
-
-
Kantarjian, H.1
O'Brien, S.2
Ravandi, F.3
-
98
-
-
34548219420
-
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
-
Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.23
, pp. 3503-3510
-
-
Malcovati, L.1
Germing, U.2
Kuendgen, A.3
-
99
-
-
80053186861
-
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
-
Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433-1440.
-
(2011)
Haematologica
, vol.96
, Issue.10
, pp. 1433-1440
-
-
Malcovati, L.1
Della Porta, M.G.2
Strupp, C.3
-
100
-
-
77950539091
-
Prognostic classification and risk assessment in myelodysplastic syndromes
-
Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):459-468.
-
(2010)
Hematol Oncol Clin North Am
, vol.24
, Issue.2
, pp. 459-468
-
-
Cazzola, M.1
Malcovati, L.2
-
101
-
-
84866621729
-
Revised international prognostic scoring system for myelodysplastic syndromes
-
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
-
(2012)
Blood
, vol.120
, Issue.12
, pp. 2454-2465
-
-
Greenberg, P.L.1
Tuechler, H.2
Schanz, J.3
-
102
-
-
53449086307
-
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome
-
Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood. 2008;112(7):2681-2686.
-
(2008)
Blood
, vol.112
, Issue.7
, pp. 2681-2686
-
-
Scott, B.L.1
Wells, D.A.2
Loken, M.R.3
Myerson, D.4
Leisenring, W.M.5
Deeg, H.J.6
-
103
-
-
77950363324
-
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment
-
Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ, van de Loosdrecht AA. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood. 2010;115(9):1779-1784.
-
(2010)
Blood
, vol.115
, Issue.9
, pp. 1779-1784
-
-
Westers, T.M.1
Alhan, C.2
Chamuleau, M.E.3
Van Der Vorst, M.J.4
Eeltink, C.5
Ossenkoppele, G.J.6
Van De Loosdrecht, A.A.7
-
104
-
-
0030056556
-
Prognostic factors in myelodysplastic syndromes: Critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques
-
Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol. 1996;94(1):116-119.
-
(1996)
Br J Haematol
, vol.94
, Issue.1
, pp. 116-119
-
-
Morel, P.1
Declercq, C.2
Hebbar, M.3
Bauters, F.4
Fenaux, P.5
-
105
-
-
0002391815
-
The clinical evaluation of chemotherapeutic agents in cancer
-
Macleod C, ed, New York, NY: Columbia University Press
-
Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod C, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:199-205.
-
(1949)
Evaluation of Chemotherapeutic Agents
, pp. 199-205
-
-
Karnofsky, D.A.1
Burchenal, J.H.2
-
106
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
-
(1982)
Am J Clin Oncol.
, vol.5
, Issue.6
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
Horton, J.4
Davis, T.E.5
McFadden, E.T.6
Carbone, P.P.7
-
107
-
-
66049093852
-
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome
-
Zipperer E, Pelz D, Nachtkamp K, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94(5):729-732.
-
(2009)
Haematologica
, vol.94
, Issue.5
, pp. 729-732
-
-
Zipperer, E.1
Pelz, D.2
Nachtkamp, K.3
-
108
-
-
77956397358
-
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries
-
Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.17
, pp. 2847-2852
-
-
Goldberg, S.L.1
Chen, E.2
Corral, M.3
Guo, A.4
Mody-Patel, N.5
Pecora, A.L.6
Laouri, M.7
-
109
-
-
70449464264
-
Comorbidity as prognostic variable in MDS: Comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group
-
Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114-119.
-
(2010)
Ann Oncol.
, vol.21
, Issue.1
, pp. 114-119
-
-
Sperr, W.R.1
Wimazal, F.2
Kundi, M.3
-
110
-
-
66049088292
-
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome
-
Della Porta MG, Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica. 2009;94(5):602-606.
-
(2009)
Haematologica
, vol.94
, Issue.5
, pp. 602-606
-
-
Della Porta, M.G.1
Malcovati, L.2
-
111
-
-
79952346792
-
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
-
Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441-449.
-
(2011)
Haematologica
, vol.96
, Issue.3
, pp. 441-449
-
-
Della Porta, M.G.1
Malcovati, L.2
Strupp, C.3
-
112
-
-
34948869819
-
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
-
Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246-4254.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.27
, pp. 4246-4254
-
-
Sorror, M.L.1
Sandmaier, B.M.2
Storer, B.E.3
-
113
-
-
79957943933
-
Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model
-
Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29(16):2240-2246.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.16
, pp. 2240-2246
-
-
Naqvi, K.1
Garcia-Manero, G.2
Sardesai, S.3
-
114
-
-
0034554786
-
Report of an international working group to standardize response criteria for myelodysplastic syndromes
-
World Health Organization WHO international working group
-
Cheson BD, Bennett JM, Kantarjian H, et al; World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-3674.
-
(2000)
Blood
, vol.96
, Issue.12
, pp. 3671-3674
-
-
Cheson, B.D.1
Bennett, J.M.2
Kantarjian, H.3
-
115
-
-
33745968917
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 419-425
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
-
116
-
-
70349502130
-
Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review
-
Pinchon DJ, Stanworth SJ, Dorée C, Brunskill S, Norfolk DR. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol. 2009;84(10):671-677.
-
(2009)
Am J Hematol
, vol.84
, Issue.10
, pp. 671-677
-
-
Pinchon, D.J.1
Stanworth, S.J.2
Dorée, C.3
Brunskill, S.4
Norfolk, D.R.5
-
117
-
-
0037092962
-
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study
-
Kornblith AB, Herndon JE II, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20(10):2441-2452.
-
(2002)
J Clin Oncol.
, vol.20
, Issue.10
, pp. 2441-2452
-
-
Kornblith, A.B.1
Herndon II, J.E.2
Silverman, L.R.3
-
118
-
-
77953527063
-
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: Efficacy and quality of life
-
Oliva EN, Nobile F, Alimena G, et al. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma. 2010;51(6):1007-1014.
-
(2010)
Leuk Lymphoma
, vol.51
, Issue.6
, pp. 1007-1014
-
-
Oliva, E.N.1
Nobile, F.2
Alimena, G.3
-
119
-
-
84860405224
-
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of 6 120 g/L with darbepoetin alfa 6 filgrastim or erythrocyte transfusions
-
Nilsson-Ehle H, Birgegård G, Samuelsson J, et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of 6 120 g/L with darbepoetin alfa 6 filgrastim or erythrocyte transfusions. Eur J Haematol. 2011;87(3):244-252.
-
(2011)
Eur J Haematol
, vol.87
, Issue.3
, pp. 244-252
-
-
Nilsson-Ehle, H.1
Birgegård, G.2
Samuelsson, J.3
-
120
-
-
79956294708
-
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
-
Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-1996.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.15
, pp. 1987-1996
-
-
Lübbert, M.1
Suciu, S.2
Baila, L.3
-
121
-
-
0027273995
-
Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report
-
Aloe Spiriti MA, Petti MC, Latagliata R, et al. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report. Haematologica. 1993;78(2):123-126.
-
(1993)
Haematologica
, vol.78
, Issue.2
, pp. 123-126
-
-
Aloe Spiriti, M.A.1
Petti, M.C.2
Latagliata, R.3
-
122
-
-
3142619150
-
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colonystimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial
-
Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colonystimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104(2):321-327.
-
(2004)
Blood
, vol.104
, Issue.2
, pp. 321-327
-
-
Casadevall, N.1
Durieux, P.2
Dubois, S.3
-
123
-
-
15244363923
-
Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome
-
Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18(4):809-816.
-
(2004)
Leukemia
, vol.18
, Issue.4
, pp. 809-816
-
-
Sekeres, M.A.1
Stone, R.M.2
Zahrieh, D.3
-
124
-
-
70350512346
-
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
-
Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114(12):2393-2400.
-
(2009)
Blood
, vol.114
, Issue.12
, pp. 2393-2400
-
-
Greenberg, P.L.1
Sun, Z.2
Miller, K.B.3
-
125
-
-
3142580475
-
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome
-
Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579-585.
-
(2004)
Blood
, vol.104
, Issue.2
, pp. 579-585
-
-
Cutler, C.S.1
Lee, S.J.2
Greenberg, P.3
-
126
-
-
0031854181
-
Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey
-
European Blood and Marrow Transplantation Group
-
Arnold R, de Witte T, van Biezen A, et al; European Blood and Marrow Transplantation Group. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. Bone Marrow Transplant. 1998;21(12):1213-1216.
-
(1998)
Bone Marrow Transplant
, vol.21
, Issue.12
, pp. 1213-1216
-
-
Arnold, R.1
De Witte, T.2
Van Biezen, A.3
-
127
-
-
0035889123
-
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
-
de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001;98(8):2326-2331.
-
(2001)
Blood
, vol.98
, Issue.8
, pp. 2326-2331
-
-
De Witte, T.1
Suciu, S.2
Verhoef, G.3
-
128
-
-
0036720739
-
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies
-
Canadian Bone Marrow Transplant Group
-
Couban S, Simpson DR, Barnett MJ, et al; Canadian Bone Marrow Transplant Group. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100(5):1525-1531.
-
(2002)
Blood
, vol.100
, Issue.5
, pp. 1525-1531
-
-
Couban, S.1
Simpson, D.R.2
Barnett, M.J.3
-
129
-
-
0037097739
-
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
-
Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group
-
Guardiola P, Runde V, Bacigalupo A, et al; Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2002;99(12):4370-4378.
-
(2002)
Blood
, vol.99
, Issue.12
, pp. 4370-4378
-
-
Guardiola, P.1
Runde, V.2
Bacigalupo, A.3
-
130
-
-
0037105374
-
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia
-
Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100(6):1997-2004.
-
(2002)
Blood
, vol.100
, Issue.6
, pp. 1997-2004
-
-
Sierra, J.1
Pérez, W.S.2
Rozman, C.3
-
131
-
-
0038189644
-
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: Results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
-
Oosterveld M, Suciu S, Verhoef G, et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 2003;17(5):859-868.
-
(2003)
Leukemia
, vol.17
, Issue.5
, pp. 859-868
-
-
Oosterveld, M.1
Suciu, S.2
Verhoef, G.3
-
132
-
-
33746661102
-
Retrospective comparison of reducedintensity conditioning and conventional highdose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
-
Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group
-
Martino R, Iacobelli S, Brand R, et al; Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reducedintensity conditioning and conventional highdose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108(3):836-846.
-
(2006)
Blood
, vol.108
, Issue.3
, pp. 836-846
-
-
Martino, R.1
Iacobelli, S.2
Brand, R.3
-
133
-
-
75749124680
-
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia
-
Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28(3):405-411.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.3
, pp. 405-411
-
-
Lim, Z.1
Brand, R.2
Martino, R.3
-
134
-
-
0033776686
-
Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
-
de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110(3):620-630.
-
(2000)
Br J Haematol
, vol.110
, Issue.3
, pp. 620-630
-
-
De Witte, T.1
Hermans, J.2
Vossen, J.3
-
135
-
-
0034651960
-
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
-
Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95(4):1188-1194.
-
(2000)
Blood
, vol.95
, Issue.4
, pp. 1188-1194
-
-
Deeg, H.J.1
Shulman, H.M.2
Anderson, J.E.3
-
136
-
-
20644462576
-
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
-
Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol. 2005;23(15):3439-3446.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.15
, pp. 3439-3446
-
-
Wallen, H.1
Gooley, T.A.2
Deeg, H.J.3
-
137
-
-
13344282097
-
Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors
-
Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996;87(1):51-58.
-
(1996)
Blood
, vol.87
, Issue.1
, pp. 51-58
-
-
Anderson, J.E.1
Appelbaum, F.R.2
Schoch, G.3
-
138
-
-
37349118061
-
Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation
-
Lee SJ, Klein J, Haagenson M, et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583.
-
(2007)
Blood
, vol.110
, Issue.13
, pp. 4576-4583
-
-
Lee, S.J.1
Klein, J.2
Haagenson, M.3
-
139
-
-
34247163959
-
Allogeneic marrow stem-cell transplantation from human leukocyte antigenidentical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy
-
French Society of Bone Marrow Transplantation and Cell Therapy
-
Yakoub-Agha I, Mesnil F, Kuentz M, et al; French Society of Bone Marrow Transplantation and Cell Therapy. Allogeneic marrow stem-cell transplantation from human leukocyte antigenidentical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24(36):5695-5702.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.36
, pp. 5695-5702
-
-
Yakoub-Agha, I.1
Mesnil, F.2
Kuentz, M.3
-
140
-
-
33751532699
-
Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors
-
IMUST Study Participating Centers; Late Effects Working Party of the European Group for Blood and Marrow Transplantation EBMT
-
Hows JM, Passweg JR, Tichelli A, et al; IMUST Study Participating Centers; Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transplant. 2006;38(12):799-805.
-
(2006)
Bone Marrow Transplant
, vol.38
, Issue.12
, pp. 799-805
-
-
Hows, J.M.1
Passweg, J.R.2
Tichelli, A.3
-
141
-
-
84871752557
-
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
-
Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myé lodysplasies. J Clin Oncol. 2012;30(36):4533-4540.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.36
, pp. 4533-4540
-
-
Damaj, G.1
Duhamel, A.2
Robin, M.3
-
142
-
-
84864018433
-
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS
-
Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18(8):1211-1218.
-
(2012)
Biol Blood Marrow Transplant
, vol.18
, Issue.8
, pp. 1211-1218
-
-
Gerds, A.T.1
Gooley, T.A.2
Estey, E.H.3
Appelbaum, F.R.4
Deeg, H.J.5
Scott, B.L.6
-
143
-
-
18744437859
-
Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: Influence of stem cell source on outcome
-
Russell JA, Larratt L, Brown C, et al. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant. 1999;24(11):1177-1183.
-
(1999)
Bone Marrow Transplant
, vol.24
, Issue.11
, pp. 1177-1183
-
-
Russell, J.A.1
Larratt, L.2
Brown, C.3
-
144
-
-
0344897774
-
Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry
-
Grupo Español de Trasplante Hematopoyético
-
del Cañizo MC, Martínez C, Conde E, Vallejo C, Brunet S, Sanz G, Mateos MV; Grupo Español de Trasplante Hematopoyético. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant. 2003;32(10):987-992.
-
(2003)
Bone Marrow Transplant
, vol.32
, Issue.10
, pp. 987-992
-
-
Del Cañizo, M.C.1
Martínez, C.2
Conde, E.3
Vallejo, C.4
Brunet, S.5
Sanz, G.6
Mateos, M.V.7
-
145
-
-
84867592111
-
Peripheral-blood stem cells versus bone marrow from unrelated donors
-
Blood and Marrow Transplant Clinical Trials Network
-
Anasetti C, Logan BR, Lee SJ, et al; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
-
(2012)
N Engl J Med.
, vol.367
, Issue.16
, pp. 1487-1496
-
-
Anasetti, C.1
Logan, B.R.2
Lee, S.J.3
-
146
-
-
0037105538
-
Evidence for a graft-versusleukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes
-
AML and alloPBSCT Subcommittees of the Spanish Group for Hematopoietic Transplantation
-
Martino R, Caballero MD, Pérez-Simón JA, et al; AML and alloPBSCT Subcommittees of the Spanish Group for Hematopoietic Transplantation. Evidence for a graft-versusleukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100(6):2243- 2245.
-
(2002)
Blood
, vol.100
, Issue.6
, pp. 2243-2245
-
-
Martino, R.1
Caballero, M.D.2
Pérez-Simón, J.A.3
-
147
-
-
0038518581
-
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia
-
Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21(8):1480-1484.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.8
, pp. 1480-1484
-
-
Bertz, H.1
Potthoff, K.2
Finke, J.3
-
148
-
-
0041411503
-
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting
-
Taussig DC, Davies AJ, Cavenagh JD, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol. 2003;21(16):3060-3065.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.16
, pp. 3060-3065
-
-
Taussig, D.C.1
Davies, A.J.2
Cavenagh, J.D.3
-
149
-
-
0037438592
-
Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: Survival does not plateau until after day 200
-
Ho AY, Kenyon M, El-Hemaidi I, Devereux S, Pagliuca A, Mufti GJ. Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200. Blood. 2003;101(2):779-780.
-
(2003)
Blood
, vol.101
, Issue.2
, pp. 779-780
-
-
Ho, A.Y.1
Kenyon, M.2
El-Hemaidi, I.3
Devereux, S.4
Pagliuca, A.5
Mufti, G.J.6
-
150
-
-
3242774628
-
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
-
de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104(3):865-872.
-
(2004)
Blood
, vol.104
, Issue.3
, pp. 865-872
-
-
De Lima, M.1
Anagnostopoulos, A.2
Munsell, M.3
-
151
-
-
24944495973
-
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
-
Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-5687.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.24
, pp. 5675-5687
-
-
Schmid, C.1
Schleuning, M.2
Ledderose, G.3
Tischer, J.4
Kolb, H.J.5
-
152
-
-
24944582579
-
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome
-
van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5728-5738.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.24
, pp. 5728-5738
-
-
Van Besien, K.1
Artz, A.2
Smith, S.3
-
153
-
-
7344227279
-
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: Results of a randomized study
-
Wattel E, Solary E, Hecquet B, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol. 1998;102(4):1015-1024.
-
(1998)
Br J Haematol
, vol.102
, Issue.4
, pp. 1015-1024
-
-
Wattel, E.1
Solary, E.2
Hecquet, B.3
-
154
-
-
0033046551
-
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia
-
Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia. 1999;13(6):843-849.
-
(1999)
Leukemia
, vol.13
, Issue.6
, pp. 843-849
-
-
Archimbaud, E.1
Jehn, U.2
Thomas, X.3
-
155
-
-
7344222651
-
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS
-
Bernasconi C, Alessandrino EP, Bernasconi P, et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol. 1998;102(3):678-683.
-
(1998)
Br J Haematol
, vol.102
, Issue.3
, pp. 678-683
-
-
Bernasconi, C.1
Alessandrino, E.P.2
Bernasconi, P.3
-
156
-
-
1842290990
-
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes
-
Verbeek W, Wörmann B, Koch P, et al. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol. 1997;74(5):205-208.
-
(1997)
Ann Hematol
, vol.74
, Issue.5
, pp. 205-208
-
-
Verbeek, W.1
Wörmann, B.2
Koch, P.3
-
157
-
-
0033560841
-
Randomized phase II study of fludarabine 1 cytosine arabinoside 1 idarubicin 1/-all-trans retinoic acid 1/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
-
Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine 1 cytosine arabinoside 1 idarubicin 1/-all-trans retinoic acid 1/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93(8):2478-2484.
-
(1999)
Blood
, vol.93
, Issue.8
, pp. 2478-2484
-
-
Estey, E.H.1
Thall, P.F.2
Pierce, S.3
-
158
-
-
0032818327
-
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: A report from the HOVON Cooperative Group
-
Dutch-Belgian Hemato-Oncology Cooperative Group
-
Ossenkoppele GJ, van der Holt B, Verhoef GE, et al; Dutch-Belgian Hemato-Oncology Cooperative Group. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Leukemia. 1999;13(8):1207-1213.
-
(1999)
Leukemia
, vol.13
, Issue.8
, pp. 1207-1213
-
-
Ossenkoppele, G.J.1
Van Der Holt, B.2
Verhoef, G.E.3
-
159
-
-
1842457644
-
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
-
Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004;22(6):1078-1086.
-
(2004)
J Clin Oncol.
, vol.22
, Issue.6
, pp. 1078-1086
-
-
Greenberg, P.L.1
Lee, S.J.2
Advani, R.3
-
160
-
-
11144358126
-
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
-
Dutch-Belgian Hemato-Oncology Cooperative Group HOVON
-
Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood. 2004;103(8):2908-2913.
-
(2004)
Blood
, vol.103
, Issue.8
, pp. 2908-2913
-
-
Ossenkoppele, G.J.1
Graveland, W.J.2
Sonneveld, P.3
-
161
-
-
20944431600
-
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
-
Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005;29(6):649-652.
-
(2005)
Leuk Res.
, vol.29
, Issue.6
, pp. 649-652
-
-
Giles, F.J.1
Kantarjian, H.M.2
Cortes, J.E.3
-
162
-
-
34547201150
-
Intensive chemotherapy is not recommended for patients aged. 60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes
-
Knipp S, Hildebrand B, Kündgen A, et al. Intensive chemotherapy is not recommended for patients aged. 60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer. 2007;110(2):345-352.
-
(2007)
Cancer
, vol.110
, Issue.2
, pp. 345-352
-
-
Knipp, S.1
Hildebrand, B.2
Kündgen, A.3
-
163
-
-
0141707699
-
The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups
-
Oosterveld M, Wittebol SH, Lemmens WA, et al. The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. Br J Haematol. 2003;123(1):81-89.
-
(2003)
Br J Haematol
, vol.123
, Issue.1
, pp. 81-89
-
-
Oosterveld, M.1
Wittebol, S.H.2
Lemmens, W.A.3
-
164
-
-
0030765385
-
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
-
Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90(8):2969-2977.
-
(1997)
Blood
, vol.90
, Issue.8
, pp. 2969-2977
-
-
Estey, E.1
Thall, P.2
Beran, M.3
Kantarjian, H.4
Pierce, S.5
Keating, M.6
-
165
-
-
0031869587
-
Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission
-
Delforge M, Demuynck H, Verhoef G, et al. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol. 1998;102(2):486-494.
-
(1998)
Br J Haematol
, vol.102
, Issue.2
, pp. 486-494
-
-
Delforge, M.1
Demuynck, H.2
Verhoef, G.3
-
166
-
-
0035886640
-
High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate-adjusted comparison of five regimens
-
Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 2001;92(8):1999-2015.
-
(2001)
Cancer
, vol.92
, Issue.8
, pp. 1999-2015
-
-
Beran, M.1
Shen, Y.2
Kantarjian, H.3
-
167
-
-
0036739696
-
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors
-
EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center
-
Oosterveld M, Muus P, Suciu S, et al; EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia. 2002;16(9):1615-1621.
-
(2002)
Leukemia
, vol.16
, Issue.9
, pp. 1615-1621
-
-
Oosterveld, M.1
Muus, P.2
Suciu, S.3
-
168
-
-
77957790347
-
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial
-
de Witte T, Hagemeijer A, Suciu S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica. 2010;95(10):1754-1761.
-
(2010)
Haematologica
, vol.95
, Issue.10
, pp. 1754-1761
-
-
De Witte, T.1
Hagemeijer, A.2
Suciu, S.3
-
169
-
-
0029823554
-
ICE, mini-ICE or highdose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia
-
Carella AM, Frassoni F. ICE, mini-ICE or highdose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia. Br J Haematol. 1996;95(1):213-215.
-
(1996)
Br J Haematol
, vol.95
, Issue.1
, pp. 213-215
-
-
Carella, A.M.1
Frassoni, F.2
-
170
-
-
0030900945
-
A randomized trial of high-vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia
-
Feldman EJ, Seiter K, Damon L, et al. A randomized trial of high-vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 1997;11(4):485-489.
-
(1997)
Leukemia
, vol.11
, Issue.4
, pp. 485-489
-
-
Feldman, E.J.1
Seiter, K.2
Damon, L.3
-
171
-
-
0032958233
-
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myélöides
-
Wattel E, Solary E, Leleu X, et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myélöides. Leukemia. 1999;13(4):524-529.
-
(1999)
Leukemia
, vol.13
, Issue.4
, pp. 524-529
-
-
Wattel, E.1
Solary, E.2
Leleu, X.3
-
172
-
-
0033571328
-
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes
-
Ferrara F, Leoni F, Pinto A, et al. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer. 1999;86(10):2006-2013.
-
(1999)
Cancer
, vol.86
, Issue.10
, pp. 2006-2013
-
-
Ferrara, F.1
Leoni, F.2
Pinto, A.3
-
173
-
-
33644553459
-
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
-
Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006;106(5):1099-1109.
-
(2006)
Cancer
, vol.106
, Issue.5
, pp. 1099-1109
-
-
Kantarjian, H.1
Beran, M.2
Cortes, J.3
-
174
-
-
62849104641
-
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
-
International Vidaza High-Risk MDS Survival Study Group
-
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
-
(2009)
Lancet Oncol.
, vol.10
, Issue.3
, pp. 223-232
-
-
Fenaux, P.1
Mufti, G.J.2
Hellstrom-Lindberg, E.3
-
175
-
-
0030729822
-
Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
-
Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation
-
De Witte T, Van Biezen A, Hermans J, et al; Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood. 1997;90(10):3853-3857.
-
(1997)
Blood
, vol.90
, Issue.10
, pp. 3853-3857
-
-
De Witte, T.1
Van Biezen, A.2
Hermans, J.3
-
176
-
-
0035195496
-
Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: Comparison with unrelated donor transplantation and autologous stem cell transplantation
-
EBMT, CLWP-MDS subcommittee
-
de Witte T, Pikkemaat F, Hermans J, et al; EBMT, CLWP-MDS subcommittee. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia. 2001;15(12):1878-1884.
-
(2001)
Leukemia
, vol.15
, Issue.12
, pp. 1878-1884
-
-
De Witte, T.1
Pikkemaat, F.2
Hermans, J.3
-
177
-
-
33745003472
-
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
-
Büchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24(16):2480-2489.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.16
, pp. 2480-2489
-
-
Büchner, T.1
Berdel, W.E.2
Schoch, C.3
-
178
-
-
0022873032
-
A critical appraisal of low-dose cytosine arabinoside in patients with acute nonlymphocytic leukemia and myelodysplastic syndromes
-
Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute nonlymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol. 1986;4(12):1857-1864.
-
(1986)
J Clin Oncol.
, vol.4
, Issue.12
, pp. 1857-1864
-
-
Cheson, B.D.1
Jasperse, D.M.2
Simon, R.3
Friedman, M.A.4
-
179
-
-
0023352145
-
Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: A review of 20 years' experience
-
Cheson BD, Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol. 1987;14(2 Suppl 1):126-133.
-
(1987)
Semin Oncol.
, vol.14
, Issue.2 SUPPL. 1
, pp. 126-133
-
-
Cheson, B.D.1
Simon, R.2
-
180
-
-
0023202025
-
A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome
-
Clark RE, Ismail SA, Jacobs A, Payne H, Smith SA. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol. 1987;66(1):77-83.
-
(1987)
Br J Haematol
, vol.66
, Issue.1
, pp. 77-83
-
-
Clark, R.E.1
Ismail, S.A.2
Jacobs, A.3
Payne, H.4
Smith, S.A.5
-
181
-
-
0024948040
-
Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes
-
EORTC Leukemia Group
-
Gerhartz HH, Visani G, Delmer A, et al; EORTC Leukemia Group. Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. Bone Marrow Transplant. 1989;4(Suppl 3):36-37.
-
(1989)
Bone Marrow Transplant
, vol.4
, Issue.SUPPL. 3
, pp. 36-37
-
-
Gerhartz, H.H.1
Visani, G.2
Delmer, A.3
-
182
-
-
0025649846
-
Treatment of myelodysplastic syndromes with retinoic acid and 1 alphahydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study
-
Scandinavian Myelodysplasia Group SMG
-
Hellström E, Robèrt KH, Samuelsson J, et al; The Scandinavian Myelodysplasia Group (SMG). Treatment of myelodysplastic syndromes with retinoic acid and 1 alphahydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. Eur J Haematol. 1990;45(5):255-261.
-
(1990)
Eur J Haematol
, vol.45
, Issue.5
, pp. 255-261
-
-
Hellström, E.1
Robèrt, K.H.2
Samuelsson, J.3
-
183
-
-
0026481129
-
The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study
-
Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol. 1992;65(4):162-168.
-
(1992)
Ann Hematol
, vol.65
, Issue.4
, pp. 162-168
-
-
Miller, K.B.1
Kim, K.2
Morrison, F.S.3
-
184
-
-
0026539976
-
Treatment of myelodysplastic syndromes with human granulocyticmacrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside
-
Economopoulos T, Papageorgiou E, Stathakis N, et al. Treatment of myelodysplastic syndromes with human granulocyticmacrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside. Eur J Haematol. 1992;49(3):138-142.
-
(1992)
Eur J Haematol
, vol.49
, Issue.3
, pp. 138-142
-
-
Economopoulos, T.1
Papageorgiou, E.2
Stathakis, N.3
-
185
-
-
0026774240
-
A predictive model for the clinical response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukaemia
-
Hellström-Lindberg E, Robèrt KH, Gahrton G, Lindberg G, Forsblom AM, Kock Y, Ost A. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J Haematol. 1992;81(4):503-511.
-
(1992)
Br J Haematol
, vol.81
, Issue.4
, pp. 503-511
-
-
Hellström-Lindberg, E.1
Robèrt, K.H.2
Gahrton, G.3
Lindberg, G.4
Forsblom, A.M.5
Kock, Y.6
Ost, A.7
-
186
-
-
0028144466
-
A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia
-
EORTC Leukemia Cooperative Group
-
Gerhartz HH, Marcus R, Delmer A, et al; EORTC Leukemia Cooperative Group. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia. 1994;8(1):16-23.
-
(1994)
Leukemia
, vol.8
, Issue.1
, pp. 16-23
-
-
Gerhartz, H.H.1
Marcus, R.2
Delmer, A.3
-
187
-
-
27644562303
-
Lowdose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
-
EORTC Leukemia Cooperative Group
-
Zwierzina H, Suciu S, Loeffler-Ragg J, et al; EORTC Leukemia Cooperative Group. Lowdose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19(11):1929-1933.
-
(2005)
Leukemia
, vol.19
, Issue.11
, pp. 1929-1933
-
-
Zwierzina, H.1
Suciu, S.2
Loeffler-Ragg, J.3
-
188
-
-
15844368828
-
Low-dose melphalan for treatment of high-risk myelodysplastic syndromes
-
Omoto E, Deguchi S, Takaba S, et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia. 1996;10(4):609-614.
-
(1996)
Leukemia
, vol.10
, Issue.4
, pp. 609-614
-
-
Omoto, E.1
Deguchi, S.2
Takaba, S.3
-
189
-
-
0033952799
-
Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia
-
Denzlinger C, Bowen D, Benz D, Gelly K, Brugger W, Kanz L. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. Br J Haematol. 2000;108(1):93-95.
-
(2000)
Br J Haematol
, vol.108
, Issue.1
, pp. 93-95
-
-
Denzlinger, C.1
Bowen, D.2
Benz, D.3
Gelly, K.4
Brugger, W.5
Kanz, L.6
-
190
-
-
17444452612
-
Low-dose 5-aza-29-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
-
Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Low-dose 5-aza-29-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18(5):956-962.
-
(2000)
J Clin Oncol.
, vol.18
, Issue.5
, pp. 956-962
-
-
Wijermans, P.1
Lübbert, M.2
Verhoef, G.3
Bosly, A.4
Ravoet, C.5
Andre, M.6
Ferrant, A.7
-
191
-
-
0034883005
-
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-29-deoxycytidine
-
Lübbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-29-deoxycytidine. Br J Haematol. 2001;114(2):349-357.
-
(2001)
Br J Haematol
, vol.114
, Issue.2
, pp. 349-357
-
-
Lübbert, M.1
Wijermans, P.2
Kunzmann, R.3
-
192
-
-
0037093195
-
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
-
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
-
(2002)
J Clin Oncol.
, vol.20
, Issue.10
, pp. 2429-2440
-
-
Silverman, L.R.1
Demakos, E.P.2
Peterson, B.L.3
-
193
-
-
17644404081
-
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes
-
Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005;45(5):597-602.
-
(2005)
J Clin Pharmacol
, vol.45
, Issue.5
, pp. 597-602
-
-
Marcucci, G.1
Silverman, L.2
Eller, M.3
Lintz, L.4
Beach, C.L.5
-
194
-
-
33646071894
-
Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
-
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
-
(2006)
Cancer
, vol.106
, Issue.8
, pp. 1794-1803
-
-
Kantarjian, H.1
Issa, J.P.2
Rosenfeld, C.S.3
-
195
-
-
33846011361
-
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
-
Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57.
-
(2007)
Blood
, vol.109
, Issue.1
, pp. 52-57
-
-
Kantarjian, H.1
Oki, Y.2
Garcia-Manero, G.3
-
196
-
-
33748474416
-
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
-
Cancer and Leukemia Group B
-
Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-3903.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.24
, pp. 3895-3903
-
-
Silverman, L.R.1
McKenzie, D.R.2
Peterson, B.L.3
Holland, J.F.4
Backstrom, J.T.5
Beach, C.L.6
Larson, R.A.7
-
197
-
-
78650172030
-
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
-
Groupe Francophone des Myelodysplasies GFM
-
Itzykson R, Thépot S, Quesnel B, et al; Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403-411.
-
(2011)
Blood
, vol.117
, Issue.2
, pp. 403-411
-
-
Itzykson, R.1
Thépot, S.2
Quesnel, B.3
-
198
-
-
0026062644
-
Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes
-
Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood. 1991;78(7):1658-1663.
-
(1991)
Blood
, vol.78
, Issue.7
, pp. 1658-1663
-
-
Stein, R.S.1
Abels, R.I.2
Krantz, S.B.3
-
199
-
-
0032409909
-
A randomized double-blind placebocontrolled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes
-
Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes
-
Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes, Ferrini PR, Grossi A, et al. A randomized double-blind placebocontrolled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol. 1998;103(4):1070-1074.
-
(1998)
Br J Haematol
, vol.103
, Issue.4
, pp. 1070-1074
-
-
Ferrini, P.R.1
Grossi, A.2
-
200
-
-
0028953367
-
Efficacy of erythropoietin in the myelodysplastic syndromes: A metaanalysis of 205 patients from 17 studies
-
Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a metaanalysis of 205 patients from 17 studies. Br J Haematol. 1995;89(1):67-71.
-
(1995)
Br J Haematol
, vol.89
, Issue.1
, pp. 67-71
-
-
Hellström-Lindberg, E.1
-
201
-
-
0034651839
-
Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome
-
GM/EPO MDS Study Group
-
Thompson JA, Gilliland DG, Prchal JT, et al; GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood. 2000;95(4):1175-1179.
-
(2000)
Blood
, vol.95
, Issue.4
, pp. 1175-1179
-
-
Thompson, J.A.1
Gilliland, D.G.2
Prchal, J.T.3
-
202
-
-
31744444200
-
Erythropoietin plus granulocyte colonystimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: Results from a randomized singlecentre study
-
Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colonystimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized singlecentre study. Ann Hematol. 2006;85(3):174-180.
-
(2006)
Ann Hematol
, vol.85
, Issue.3
, pp. 174-180
-
-
Balleari, E.1
Rossi, E.2
Clavio, M.3
-
203
-
-
0030682515
-
Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model
-
Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344-351.
-
(1997)
Br J Haematol
, vol.99
, Issue.2
, pp. 344-351
-
-
Hellström-Lindberg, E.1
Negrin, R.2
Stein, R.3
-
204
-
-
0037353935
-
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin 1 granulocyte colony-stimulating factor: Significant effects on quality of life
-
Scandinavian MDS Group
-
Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin 1 granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-1046.
-
(2003)
Br J Haematol
, vol.120
, Issue.6
, pp. 1037-1046
-
-
Hellström-Lindberg, E.1
Gulbrandsen, N.2
Lindberg, G.3
-
205
-
-
49049116574
-
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
-
Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607-3613.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.21
, pp. 3607-3613
-
-
Jädersten, M.1
Malcovati, L.2
Dybedal, I.3
-
206
-
-
38349097652
-
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience
-
GFM group Groupe Francophone des Myélodysplasies
-
Park S, Grabar S, Kelaidi C, et al; GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-582.
-
(2008)
Blood
, vol.111
, Issue.2
, pp. 574-582
-
-
Park, S.1
Grabar, S.2
Kelaidi, C.3
-
207
-
-
28444489284
-
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
-
Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol. 2005;16(12):1921-1927.
-
(2005)
Ann Oncol.
, vol.16
, Issue.12
, pp. 1921-1927
-
-
Stasi, R.1
Abruzzese, E.2
Lanzetta, G.3
Terzoli, E.4
Amadori, S.5
-
208
-
-
19944432966
-
Darbepoetin alpha for the treatment of anaemia in lowintermediate risk myelodysplastic syndromes
-
Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in lowintermediate risk myelodysplastic syndromes. Br J Haematol. 2005;128(2):204-209.
-
(2005)
Br J Haematol
, vol.128
, Issue.2
, pp. 204-209
-
-
Musto, P.1
Lanza, F.2
Balleari, E.3
-
209
-
-
33845563409
-
Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes
-
Aranesp in Myelodysplastic Syndromes ARM Study Group
-
Giraldo P, Nomdedeu B, Loscertales J, et al; Aranesp in Myelodysplastic Syndromes (ARM) Study Group. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer. 2006;107(12):2807-2816.
-
(2006)
Cancer
, vol.107
, Issue.12
, pp. 2807-2816
-
-
Giraldo, P.1
Nomdedeu, B.2
Loscertales, J.3
-
210
-
-
33646237362
-
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
-
Groupe Francais des Myelodysplasies
-
Mannone L, Gardin C, Quarre MC, et al; Groupe Francais des Myelodysplasies. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol. 2006;133(5):513-519.
-
(2006)
Br J Haematol
, vol.133
, Issue.5
, pp. 513-519
-
-
Mannone, L.1
Gardin, C.2
Quarre, M.C.3
-
211
-
-
46949086842
-
Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
-
Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008;142(3):379-393.
-
(2008)
Br J Haematol
, vol.142
, Issue.3
, pp. 379-393
-
-
Gabrilove, J.1
Paquette, R.2
Lyons, R.M.3
Mushtaq, C.4
Sekeres, M.A.5
Tomita, D.6
Dreiling, L.7
-
212
-
-
58149472365
-
A Phase II intrapatient dose-escalation trial of weight-based darbepoetin alfa with or without granulocytecolony stimulating factor in myelodysplastic syndromes
-
Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL. A Phase II intrapatient dose-escalation trial of weight-based darbepoetin alfa with or without granulocytecolony stimulating factor in myelodysplastic syndromes. Am J Hematol. 2009;84(1):15-20.
-
(2009)
Am J Hematol
, vol.84
, Issue.1
, pp. 15-20
-
-
Gotlib, J.1
Lavori, P.2
Quesada, S.3
Stein, R.S.4
Shahnia, S.5
Greenberg, P.L.6
-
213
-
-
79954506128
-
Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response
-
Villegas A, Arrizabalaga B, Fernández-Lago C, et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin. 2011;27(5):951-960.
-
(2011)
Curr Med Res Opin
, vol.27
, Issue.5
, pp. 951-960
-
-
Villegas, A.1
Arrizabalaga, B.2
Fernández-Lago, C.3
-
214
-
-
0036197002
-
Epoetin omega for treatment of anemia in maintenance hemodialysis patients
-
Sikole A, Spasovski G, Zafirov D, Polenakovic M. Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol. 2002;57(3):237-245.
-
(2002)
Clin Nephrol
, vol.57
, Issue.3
, pp. 237-245
-
-
Sikole, A.1
Spasovski, G.2
Zafirov, D.3
Polenakovic, M.4
-
215
-
-
36048947690
-
Epoetin delta in the management of renal anaemia: Results of a 6-month study
-
Epoetin Delta 3001 Study Group
-
Martin KJ; Epoetin Delta 3001 Study Group. Epoetin delta in the management of renal anaemia: results of a 6-month study. Nephrol Dial Transplant. 2007;22(10):3052-3054.
-
(2007)
Nephrol Dial Transplant
, vol.22
, Issue.10
, pp. 3052-3054
-
-
Martin, K.J.1
-
216
-
-
67650489060
-
Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia
-
Epoetin Zeta Oncology Study Group
-
Tzekova V, Mihaylov G, Elezovic I, Koytchev R; Epoetin Zeta Oncology Study Group. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin. 2009;25(7):1689-1697.
-
(2009)
Curr Med Res Opin
, vol.25
, Issue.7
, pp. 1689-1697
-
-
Tzekova, V.1
Mihaylov, G.2
Elezovic, I.3
Koytchev, R.4
-
217
-
-
65349147154
-
HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours
-
Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie. 2009;32(4):168-174.
-
(2009)
Onkologie
, vol.32
, Issue.4
, pp. 168-174
-
-
Weigang-Köhler, K.1
Vetter, A.2
Thyroff-Friesinger, U.3
-
218
-
-
84864487642
-
Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
-
Aapro M, Cornes P, Sun D, Abraham I. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis- stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012;4(3):95-105.
-
(2012)
Ther Adv Med Oncol.
, vol.4
, Issue.3
, pp. 95-105
-
-
Aapro, M.1
Cornes, P.2
Sun, D.3
Abraham, I.4
-
219
-
-
84855436897
-
Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetina (HX575) in non-dialysis patients with renal anemia: A multi-center, randomized, doubleblind study
-
Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetina (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, doubleblind study. Clin Nephrol. 2012;77(1):8-17.
-
(2012)
Clin Nephrol
, vol.77
, Issue.1
, pp. 8-17
-
-
Haag-Weber, M.1
Eckardt, K.U.2
Hörl, W.H.3
Roger, S.D.4
Vetter, A.5
Roth, K.6
-
220
-
-
75749124291
-
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia
-
Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28(3):437-444.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.3
, pp. 437-444
-
-
Kantarjian, H.1
Fenaux, P.2
Sekeres, M.A.3
-
221
-
-
79952011926
-
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes
-
Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011;117(5):992-1000.
-
(2011)
Cancer
, vol.117
, Issue.5
, pp. 992-1000
-
-
Sekeres, M.A.1
Kantarjian, H.2
Fenaux, P.3
-
222
-
-
78049378253
-
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
-
Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116(17):3163-3170.
-
(2010)
Blood
, vol.116
, Issue.17
, pp. 3163-3170
-
-
Kantarjian, H.M.1
Giles, F.J.2
Greenberg, P.L.3
-
223
-
-
84870882367
-
Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): Results of a randomized, double-blind, placebo (PBO)-controlled study [abstract]
-
Abstract 117
-
Giagounidis A, Mufti GJ, Kantarjian HM, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo (PBO)-controlled study [abstract]. Blood. 2011;118(21). Abstract 117.
-
(2011)
Blood
, vol.118
, Issue.21
-
-
Giagounidis, A.1
Mufti, G.J.2
Kantarjian, H.M.3
-
224
-
-
84888231265
-
Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): Follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study [abstract]
-
Abstract 421
-
Kantarjian HM, Mufti GJ, Fenaux P, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study [abstract]. Blood. 2012;120(21). Abstract 421.
-
(2012)
Blood
, vol.120
, Issue.21
-
-
Kantarjian, H.M.1
Mufti, G.J.2
Fenaux, P.3
-
225
-
-
84879505047
-
Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Interim analysis of a prospective, randomized, singleblind, placebo-controlled trial (EQoL-MDS) [abstract]
-
Abstract 923
-
Oliva EN, Santini V, Zini G, et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, singleblind, placebo-controlled trial (EQoL-MDS) [abstract]. Blood. 2012;120(21). Abstract 923.
-
(2012)
Blood
, vol.120
, Issue.21
-
-
Oliva, E.N.1
Santini, V.2
Zini, G.3
-
226
-
-
84894901142
-
Eltrombopag treatment of thrombocytopenia in advanced myelodysplastic syndromes and acute myeloid leukemia: Results of the 8-week openlabel part of an ongoing study [abstract]
-
Abstract 3822
-
Mittelman M, Assouline S, Briasoulis E, et al. Eltrombopag treatment of thrombocytopenia in advanced myelodysplastic syndromes and acute myeloid leukemia: results of the 8-week openlabel part of an ongoing study [abstract]. Blood. 2012;120(21). Abstract 3822.
-
(2012)
Blood
, vol.120
, Issue.21
-
-
Mittelman, M.1
Assouline, S.2
Briasoulis, E.3
-
227
-
-
0035883101
-
Thalidomide produces transfusion independence in longstanding refractory anemias of patients with myelodysplastic syndromes
-
Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in longstanding refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98(4):958-965.
-
(2001)
Blood
, vol.98
, Issue.4
, pp. 958-965
-
-
Raza, A.1
Meyer, P.2
Dutt, D.3
-
228
-
-
0035986788
-
Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes
-
Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, Carella AM. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002;87(8):884-886.
-
(2002)
Haematologica
, vol.87
, Issue.8
, pp. 884-886
-
-
Musto, P.1
Falcone, A.2
Sanpaolo, G.3
Bisceglia, M.4
Matera, R.5
Carella, A.M.6
-
229
-
-
0036155876
-
Thalidomide for the treatment of patients with myelodysplastic syndromes
-
Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16(1):1-6.
-
(2002)
Leukemia
, vol.16
, Issue.1
, pp. 1-6
-
-
Strupp, C.1
Germing, U.2
Aivado, M.3
Misgeld, E.4
Haas, R.5
Gattermann, N.6
-
230
-
-
13444256401
-
Efficacy of lenalidomide in myelodysplastic syndromes
-
List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
-
(2005)
N Engl J Med.
, vol.352
, Issue.6
, pp. 549-557
-
-
List, A.1
Kurtin, S.2
Roe, D.J.3
-
231
-
-
33749438404
-
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
-
Myelodysplastic Syndrome-003 Study Investigators
-
List A, Dewald G, Bennett J, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
-
(2006)
N Engl J Med.
, vol.355
, Issue.14
, pp. 1456-1465
-
-
List, A.1
Dewald, G.2
Bennett, J.3
-
232
-
-
38049113182
-
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
-
Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
-
(2008)
Blood
, vol.111
, Issue.1
, pp. 86-93
-
-
Raza, A.1
Reeves, J.A.2
Feldman, E.J.3
-
233
-
-
80053621748
-
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
-
MDS-004 Lenalidomide del5q Study Group
-
Fenaux P, Giagounidis A, Selleslag D, et al; MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-3776.
-
(2011)
Blood
, vol.118
, Issue.14
, pp. 3765-3776
-
-
Fenaux, P.1
Giagounidis, A.2
Selleslag, D.3
-
234
-
-
39849099704
-
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
-
Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008;5(2):e35.
-
(2008)
PLoS Med.
, vol.5
, Issue.2
-
-
Ebert, B.L.1
Galili, N.2
Tamayo, P.3
-
235
-
-
0030695069
-
Antithymocyte globulin for patients with myelodysplastic syndrome
-
Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99(3):699-705.
-
(1997)
Br J Haematol
, vol.99
, Issue.3
, pp. 699-705
-
-
Molldrem, J.J.1
Caples, M.2
Mavroudis, D.3
Plante, M.4
Young, N.S.5
Barrett, A.J.6
-
236
-
-
0037031289
-
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes
-
Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002;137(3):156-163.
-
(2002)
Ann Intern Med.
, vol.137
, Issue.3
, pp. 156-163
-
-
Molldrem, J.J.1
Leifer, E.2
Bahceci, E.3
-
237
-
-
0036720903
-
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome
-
Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570-1574.
-
(2002)
Blood
, vol.100
, Issue.5
, pp. 1570-1574
-
-
Saunthararajah, Y.1
Nakamura, R.2
Nam, J.M.3
-
238
-
-
20244381363
-
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells
-
Aivado M, Rong A, Stadler M, et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol. 2002;68(4):210-216.
-
(2002)
Eur J Haematol
, vol.68
, Issue.4
, pp. 210-216
-
-
Aivado, M.1
Rong, A.2
Stadler, M.3
-
239
-
-
0141923848
-
A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
-
Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102(8):3025-3027.
-
(2003)
Blood
, vol.102
, Issue.8
, pp. 3025-3027
-
-
Saunthararajah, Y.1
Nakamura, R.2
Wesley, R.3
Wang, Q.J.4
Barrett, A.J.5
-
240
-
-
0037443455
-
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
-
Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003;101(6):2156-2158.
-
(2003)
Blood
, vol.101
, Issue.6
, pp. 2156-2158
-
-
Steensma, D.P.1
Dispenzieri, A.2
Moore, S.B.3
Schroeder, G.4
Tefferi, A.5
-
241
-
-
0345701967
-
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia
-
Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003;120(4):679-684.
-
(2003)
Br J Haematol
, vol.120
, Issue.4
, pp. 679-684
-
-
Killick, S.B.1
Mufti, G.2
Cavenagh, J.D.3
-
242
-
-
1542608520
-
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
-
Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004;18(3):460-465.
-
(2004)
Leukemia
, vol.18
, Issue.3
, pp. 460-465
-
-
Stadler, M.1
Germing, U.2
Kliche, K.O.3
-
243
-
-
23044473715
-
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
-
Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood. 2005;106(3):841-851.
-
(2005)
Blood
, vol.106
, Issue.3
, pp. 841-851
-
-
Sloand, E.M.1
Mainwaring, L.2
Fuhrer, M.3
-
244
-
-
33744492061
-
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk nonsideroblastic myelodysplastic syndromes
-
Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk nonsideroblastic myelodysplastic syndromes. Haematologica. 2006;91(5):667-670.
-
(2006)
Haematologica
, vol.91
, Issue.5
, pp. 667-670
-
-
Broliden, P.A.1
Dahl, I.M.2
Hast, R.3
-
245
-
-
34250767166
-
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
-
Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21(7):1436-1441.
-
(2007)
Leukemia
, vol.21
, Issue.7
, pp. 1436-1441
-
-
Lim, Z.Y.1
Killick, S.2
Germing, U.3
-
246
-
-
45149093744
-
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
-
Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505-2511.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.15
, pp. 2505-2511
-
-
Sloand, E.M.1
Wu, C.O.2
Greenberg, P.3
Young, N.4
Barrett, J.5
-
247
-
-
79951996237
-
Immunosuppressive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99
-
Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol. 2011;29(3):303-309.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.3
, pp. 303-309
-
-
Passweg, J.R.1
Giagounidis, A.A.2
Simcock, M.3
-
248
-
-
0015112912
-
Iron in the heart. Etiology and clinical significance
-
Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51(2):209-221.
-
(1971)
Am J Med.
, vol.51
, Issue.2
, pp. 209-221
-
-
Buja, L.M.1
Roberts, W.C.2
-
249
-
-
0019349312
-
Clinical consequences of acquired transfusional iron overload in adults
-
Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304(6):319-324.
-
(1981)
N Engl J Med.
, vol.304
, Issue.6
, pp. 319-324
-
-
Schafer, A.I.1
Cheron, R.G.2
Dluhy, R.3
Cooper, B.4
Gleason, R.E.5
Soeldner, J.S.6
Bunn, H.F.7
-
250
-
-
34547629784
-
Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions
-
Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138(5):587-593.
-
(2007)
Br J Haematol
, vol.138
, Issue.5
, pp. 587-593
-
-
Chacko, J.1
Pennell, D.J.2
Tanner, M.A.3
-
251
-
-
35548958313
-
No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique
-
Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y, Rachmilewitz E. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol. 2007;82(11):1013-1016.
-
(2007)
Am J Hematol
, vol.82
, Issue.11
, pp. 1013-1016
-
-
Konen, E.1
Ghoti, H.2
Goitein, O.3
Winder, A.4
Kushnir, T.5
Eshet, Y.6
Rachmilewitz, E.7
-
252
-
-
51049118552
-
Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias
-
Di Tucci AA, Matta G, Deplano S, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93(9):1385-1388.
-
(2008)
Haematologica
, vol.93
, Issue.9
, pp. 1385-1388
-
-
Di Tucci, A.A.1
Matta, G.2
Deplano, S.3
-
253
-
-
79960765638
-
Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes
-
Roy NB, Myerson S, Schuh AH, et al. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. Br J Haematol. 2011;154(4):521-524.
-
(2011)
Br J Haematol
, vol.154
, Issue.4
, pp. 521-524
-
-
Roy, N.B.1
Myerson, S.2
Schuh, A.H.3
-
254
-
-
34248383686
-
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
-
Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-4588.
-
(2007)
Blood
, vol.109
, Issue.10
, pp. 4586-4588
-
-
Armand, P.1
Kim, H.T.2
Cutler, C.S.3
-
255
-
-
53849087878
-
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)
-
Platzbecker U, Bornhäuser M, Germing U, et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant. 2008;14(11):1217-1225.
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, Issue.11
, pp. 1217-1225
-
-
Platzbecker, U.1
Bornhäuser, M.2
Germing, U.3
-
256
-
-
77949759009
-
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: A GITMO study
-
Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica. 2010;95(3):476-484.
-
(2010)
Haematologica
, vol.95
, Issue.3
, pp. 476-484
-
-
Alessandrino, E.P.1
Della Porta, M.G.2
Bacigalupo, A.3
-
257
-
-
77952091016
-
Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation
-
Lim ZY, Fiaccadori V, Gandhi S, et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res. 2010;34(6):723-727.
-
(2010)
Leuk Res.
, vol.34
, Issue.6
, pp. 723-727
-
-
Lim, Z.Y.1
Fiaccadori, V.2
Gandhi, S.3
-
258
-
-
79956044464
-
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation
-
Armand P, Kim HT, Rhodes J, et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):852-860.
-
(2011)
Biol Blood Marrow Transplant
, vol.17
, Issue.6
, pp. 852-860
-
-
Armand, P.1
Kim, H.T.2
Rhodes, J.3
-
259
-
-
84870361907
-
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation
-
Wermke M, Schmidt A, Middeke JM, et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res. 2012;18(23):6460-6468.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.23
, pp. 6460-6468
-
-
Wermke, M.1
Schmidt, A.2
Middeke, J.M.3
-
260
-
-
0037222940
-
Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: A study in adult patients with acquired anemias
-
Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101(1):91-96.
-
(2003)
Blood
, vol.101
, Issue.1
, pp. 91-96
-
-
Jensen, P.D.1
Jensen, F.T.2
Christensen, T.3
Nielsen, J.L.4
Ellegaard, J.5
-
261
-
-
0034192162
-
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
-
Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood. 2000;95(9):2776-2779.
-
(2000)
Blood
, vol.95
, Issue.9
, pp. 2776-2779
-
-
Franchini, M.1
Gandini, G.2
De Gironcoli, M.3
Vassanelli, A.4
Borgna-Pignatti, C.5
Aprili, G.6
-
262
-
-
0029825581
-
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial
-
Kersten MJ, Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W, Goudsmit R. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol. 1996;73(5):247-252.
-
(1996)
Ann Hematol
, vol.73
, Issue.5
, pp. 247-252
-
-
Kersten, M.J.1
Lange, R.2
Smeets, M.E.3
Vreugdenhil, G.4
Roozendaal, K.J.5
Lameijer, W.6
Goudsmit, R.7
-
263
-
-
79957438239
-
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome
-
Cermak J, Jonasova A, Vondrakova J, Walterova L, Hochova I, Siskova M, Neuwirtova R. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin. 2011;35(3):217-227.
-
(2011)
Hemoglobin
, vol.35
, Issue.3
, pp. 217-227
-
-
Cermak, J.1
Jonasova, A.2
Vondrakova, J.3
Walterova, L.4
Hochova, I.5
Siskova, M.6
Neuwirtova, R.7
-
264
-
-
38049151217
-
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study
-
Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
-
(2008)
Eur J Haematol
, vol.80
, Issue.2
, pp. 168-176
-
-
Porter, J.1
Galanello, R.2
Saglio, G.3
-
265
-
-
77950682176
-
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias
-
EPIC Study Investigators
-
Cappellini MD, Porter J, El-Beshlawy A, et al; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
-
(2010)
Haematologica
, vol.95
, Issue.4
, pp. 557-566
-
-
Cappellini, M.D.1
Porter, J.2
El-Beshlawy, A.3
-
266
-
-
77955268192
-
Deferasirox in ironoverloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
-
EPIC study investigators
-
Gattermann N, Finelli C, Porta MD, et al; EPIC study investigators. Deferasirox in ironoverloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143-1150.
-
(2010)
Leuk Res.
, vol.34
, Issue.9
, pp. 1143-1150
-
-
Gattermann, N.1
Finelli, C.2
Porta, M.D.3
-
267
-
-
84856977016
-
Deferasirox treatment of iron-overloaded chelation-näive and prechelated patients with myelodysplastic syndromes in medical practice: Results from the observational studies eXtend and eXjange
-
Gattermann N, Jarisch A, Schlag R, et al. Deferasirox treatment of iron-overloaded chelation-näive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Eur J Haematol. 2012;88(3):260-268.
-
(2012)
Eur J Haematol
, vol.88
, Issue.3
, pp. 260-268
-
-
Gattermann, N.1
Jarisch, A.2
Schlag, R.3
-
268
-
-
84865848632
-
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
-
Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97(9):1364-1371.
-
(2012)
Haematologica
, vol.97
, Issue.9
, pp. 1364-1371
-
-
Gattermann, N.1
Finelli, C.2
Della Porta, M.3
-
269
-
-
84863900001
-
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome
-
List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012;30(17):2134-2139.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.17
, pp. 2134-2139
-
-
List, A.F.1
Baer, M.R.2
Steensma, D.P.3
-
270
-
-
0025070260
-
Bone marrow transplantation in patients with thalassemia
-
Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421.
-
(1990)
N Engl J Med.
, vol.322
, Issue.7
, pp. 417-421
-
-
Lucarelli, G.1
Galimberti, M.2
Polchi, P.3
-
271
-
-
0027184519
-
Marrow transplantation in patients with thalassemia responsive to iron chelation therapy
-
Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329(12):840-844.
-
(1993)
N Engl J Med.
, vol.329
, Issue.12
, pp. 840-844
-
-
Lucarelli, G.1
Galimberti, M.2
Polchi, P.3
-
272
-
-
0031452585
-
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto
-
Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med. 1997;337(26):1870-1875.
-
(1997)
N Engl J Med.
, vol.337
, Issue.26
, pp. 1870-1875
-
-
Rebulla, P.1
Finazzi, G.2
Marangoni, F.3
-
273
-
-
0032442454
-
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10, 000/microL versus 20, 000/microL
-
Navarro JT, Hernández JA, Ribera JM, et al. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10, 000/microL versus 20, 000/microL. Haematologica. 1998;83(11):998-1000.
-
(1998)
Haematologica
, vol.83
, Issue.11
, pp. 998-1000
-
-
Navarro, J.T.1
Hernández, J.A.2
Ribera, J.M.3
-
274
-
-
0032525187
-
Safety and cost effectiveness of a 10 × 10 (9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10 (9)/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
-
Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 × 10 (9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10 (9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91(10):3601-3606.
-
(1998)
Blood
, vol.91
, Issue.10
, pp. 3601-3606
-
-
Wandt, H.1
Frank, M.2
Ehninger, G.3
-
275
-
-
78651078452
-
The European LeukemiaNet: Achievements and perspectives
-
European LeukemiaNet
-
Hehlmann R, Grimwade D, Simonsson B, et al; European LeukemiaNet. The European LeukemiaNet: achievements and perspectives. Haematologica. 2011;96(1):156-162.
-
(2011)
Haematologica
, vol.96
, Issue.1
, pp. 156-162
-
-
Hehlmann, R.1
Grimwade, D.2
Simonsson, B.3
|